Itraconazole in human medicine and veterinary practice

J Mycol Med. 2024 Jun;34(2):101473. doi: 10.1016/j.mycmed.2024.101473. Epub 2024 Mar 11.

Abstract

Diagnosis and management of fungal infections are challenging in both animals and humans, especially in immunologically weakened hosts. Due to its broad spectrum and safety profile when compared to other antifungals, itraconazole (ITZ) has been widely used in the treatment and prophylaxis of fungal infections, both in human and veterinary medicine. The dose and duration of management depend on factors such as the type of fungal pathogen, the site of infection, sensitivity to ITZ, chronic stages of the disease, the health status of the hosts, pharmacological interactions with other medications and the therapeutic protocol used. In veterinary practice, ITZ doses generally vary between 3 mg/kg and 50 mg/kg, once or twice a day. In humans, doses usually vary between 100 and 400 mg/day. As human and veterinary fungal infections are increasingly associated, and ITZ is one of the main medications used, this review addresses relevant aspects related to the use of this drug in both clinics, including case reports and different clinical aspects available in the literature.

Keywords: Fungal diseases; Humans; Itraconazole; Treatment; Veterinary.

Publication types

  • Review

MeSH terms

  • Animals
  • Antifungal Agents* / administration & dosage
  • Antifungal Agents* / therapeutic use
  • Humans
  • Itraconazole* / therapeutic use
  • Mycoses* / drug therapy
  • Mycoses* / microbiology
  • Mycoses* / veterinary
  • Veterinary Medicine / methods

Substances

  • Antifungal Agents
  • Itraconazole